The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population. METHODS: We randomly assigned 272 patients to receive nivolumab, at a dose of 3 mg per kilogram of body weight every 2 weeks, or docetaxel, at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival. RESULTS: The median overall survival was 9.2 months (95% confidence interval [CI], 7.3 to 13.3) with nivolumab versus 6.0 months (95% CI, 5.1 to 7.3) with docetaxel. The risk of death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0.001). At 1 year, the overall survival rate was 42% (95% CI, 34 to 50) with nivolumab versus 24% (95% CI, 17 to 31) with docetaxel. The response rate was 20% with nivolumab versus 9% with docetaxel (P=0.008). The median progression-free survival was 3.5 months with nivolumab versus 2.8 months with docetaxel (hazard ratio for death or disease progression, 0.62; 95% CI, 0.47 to 0.81; P<0.001). The expression of the PD-1 ligand (PD-L1) was neither prognostic nor predictive of benefit. Treatment-related adverse events of grade 3 or 4 were reported in 7% of the patients in the nivolumab group as compared with 55% of those in the docetaxel group. CONCLUSIONS: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. (Funded by Bristol-Myers Squibb; CheckMate 017 ClinicalTrials.gov number, NCT01642004.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Median time to response was 3.3 months; median duration of response had not been reached at the time of publication.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab has significantly improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers remain an unmet need.”
From SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“The development of immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 interaction has transformed the therapeutic landscape of patients with advanced non-small cell lung cancer (NSCLC) [1][2][3][4][5][6] .”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [2]
In the citing paper
“Landmark trials performed on previously treated patients with advanced NSCLC demonstrated superior overall survival (OS) with PD-1/PD-L1 blockade compared to standard chemotherapy [1][2][3] .”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [2]
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [72]
In the citing paper
“At the data cut-off, median OS was 9.2 months (95% CI: 7.3-13.3months) on nivolumab compared with 6.0 months (95% CI: 5.1-7.3months) on docetaxel, with a 41% reduction in the risk of death in the nivolumab arm (HR 0.59, 95% CI: 0.44-0.49;P < 0.001).”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“In the phase III trial, nivolumab was better tolerated than docetaxel, with 85% of nivolumab patients receiving at least 90% of their planned dose intensity, compared with 69% of docetaxel patients, together with a treatment discontinuation rate of 10% versus 3% of the patients treated with nivolumab and docetaxel, respectively.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“The primary end point was overall response rate, which occurred in 17 (14.5%) of 117 patients (95% CI 8.7 to 22.2).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
In the citing paper
“Adverse effects included dyspnea, fatigue, pneumonitis, diarrhea, musculoskeletal pain, and severe immune-mediated adverse effects98,99; 59% of patients experienced serious adverse events.100”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Self-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Research works printed but not linked: 1
- Soria JC, 2013, Eur J Cancer, 49
Cited by
Sorted by citations
Items 501–600 of 1,048
Treatment after progression in the era of immunotherapy
Billan, S., Kaidar‐Person, O., & Gil, Z. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30328-4 · Cited by 205
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213
Current progress in immunotherapy for pancreatic cancer
Foley, K., Kim, V., Jaffee, E. M., & Zheng, L. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.12.020 · Cited by 204
Brunnström, H., Johansson, A., Westbom-Fremer, S., Backman, M., Djureinovic, D., Patthey, A., Isaksson‐Mettävainio, M., Gulyás, M., & Micke, P. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.59 · Cited by 204
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 209
Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches
Uprety, D., Mandrekar, S. J., Wigle, D. A., Roden, A. C., & Adjei, A. A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.020 · Cited by 204
Tang, S., Tang, L., Mao, Y., Li, W., Chen, L., Zhang, Y., Guo, Y. Q., Liu, Q., Sun, Y. H., Xu, C., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.790 · Cited by 206
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Tison, A., Garaud, S., Chiche, L., Cornec, D., & Kostine, M. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00841-0 · Cited by 204
Nan, X., Xie, C., Yu, X., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20095 · Cited by 203
New immunotherapies targeting the PD-1 pathway
Chinai, J. M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., & Zang, X. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.005 · Cited by 202
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Schalper, K. A., Carvajal‐Hausdorf, D., McLaughlin, J. F., Altan, M., Velcheti, V., Gaule, P., Sanmamed, M. F., Chen, L., Herbst, R. S., & Rimm, D. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0150 · Cited by 202
The Role of the Estrogen Pathway in the Tumor Microenvironment
Rothenberger, N. J., Somasundaram, A., & Stabile, L. P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020611 · Cited by 202
Leonetti, A., Wever, B. M. M., Mazzaschi, G., Assaraf, Y. G., Rolfo, C. D., Quaini, F., Tiseo, M., & Giovannetti, E. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100644 · Cited by 202
Huang, J., Xu, B., Mo, H., Zhang, W., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Yang, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2439 · Cited by 201
Bello, M. G. D., Filiberti, R., Alama, A., Orengo, A. M., Mussap, M., Coco, S., Vanni, I., Boccardo, S., Rijavec, E., Genova, C., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1828-0 · Cited by 201
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R. A., Lesh, R. W., Ali, U., Kubiak, M. J., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 202
Sex- and Gender-Based Pharmacological Response to Drugs
Mauvais‐Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., Gouni‐Berthold, I., Heiman, M. L., Kautzky‐Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 203
Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 201
Self-citationKoelzer, V. H., Rothschild, S. I., Zihler, D., Wicki, A., Willi, B., Willi, N., Voegeli, M., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0117-1 · Cited by 200
Role of PD-1 in Immunity and Diseases
Chamoto, K., Al-Habsi, M., & Honjo, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_67 · Cited by 200
Chen, X., Pan, X., Zhang, W., Guo, H., Cheng, S., He, Q., Yang, B., & Ding, L. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.09.006 · Cited by 203
Immunology and immunotherapy of cholangiocarcinoma
Greten, T. F., Schwabe, R. F., Bardeesy, N. M., Ma, L., Goyal, L., Kelley, R. K., & Wang, X. W. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00741-4 · Cited by 200
Aguiar, P. N., de Mello, R. A., Hall, P. S., Tadokoro, H., & Lopes, G. D. L., Jr. (2017) · Immunotherapy · doi:10.2217/imt-2016-0150 · Cited by 199
Minguet, J., Smith, K. H., & Bramlage, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29915 · Cited by 198
Chowdhury, P. S., Chamoto, K., & Honjo, T. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12708 · Cited by 198
Manohar, S., Kompotiatis, P., Thongprayoon, C., Cheungpasitporn, W., Herrmann, J., & Herrmann, S. M. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy105 · Cited by 198
The Immune Subtypes and Landscape of Squamous Cell Carcinoma
Li, B., Cui, Y., Nambiar, D. K., Sunwoo, J. B., & Li, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4085 · Cited by 199
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Suresh, K. S., Naidoo, J., Zhong, Q., Xiong, Y., Mammen, J. S., de Flores, M. D. V., Cappelli, L. C., Balaji, A., Palmer, T., Forde, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128654 · Cited by 198
Self-citationThe impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
Wang, Y., Lee, H., Hsu, J. L., Yu, D., & Hung, M. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00670-x · Cited by 198
Cells of origin of lung cancers: lessons from mouse studiesPreprint
Ferone, G., Lee, M. C., Sage, J., & Berns, A. J. M. (2020) · Genes & Development · doi:10.1101/gad.338228.120 · Cited by 198
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
Hettich, M., Braun, F., Bartholomä, M. D., Schirmbeck, R., & Niedermann, G. (2016) · Theranostics · doi:10.7150/thno.15253 · Cited by 197
Molecular approaches for classifying endometrial carcinoma
Piulats, J. M., Guerra, E., Gil-Martín, M., Roman‐Canal, B., Gatius, S., Pamplona, R. S., Velasco, A., Vidal, A., & Matías‐Guiu, X. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.12.015 · Cited by 197
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Cabel, L., Proudhon, C., Romano, E., Girard, N., Lantz, O. J., Stern, M., Pierga, J., & Bidard, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0074-3 · Cited by 197
Early detection of lung cancer biomarkers through biosensor technology: A review
Roointan, A., Mir, T. A., Wani, S. I., Mati-ur-Rehman, Hussain, K. K., Ahmed, B., Abrahim, S., Savardashtaki, A., Gandomani, G., Gandomani, M., et al. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.10.017 · Cited by 198
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R. Y., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 197
Younes, A., Brody, J., Carpio, C. D. C., López‐Guillermo, A., Ben‐Yehuda, D., Ferhanoğlu, B., Nagler, A., Özcan, M., Avivi, I. M., Bosch, F., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30217-5 · Cited by 197
Immune Resistance in Lung Adenocarcinoma
Σπέλλα, Μ., & Stathopoulos, G. T. (2021) · Cancers · doi:10.3390/cancers13030384 · Cited by 196
Kaira, K., Higuchi, T., Naruse, I., Arisaka, Y., Tokue, A., Altan, B., Suda, S., Mogi, A., Shimizu, K., Sunaga, N., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3806-1 · Cited by 195
Remón, J., Rhun, É. L., & Besse, B. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.006 · Cited by 196
Sugawara, S., Lee, J.-S., Kang, J., Kim, H. R., Inui, N., Hida, T., Lee, K. H., Yoshida, T., Tanaka, H., Yang, C., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.004 · Cited by 195
Immune checkpoint inhibitors and elderly people: A review
Daste, A., Domblides, C., Gross‐Goupil, M., Chakiba, C., Quivy, A., Cochin, V., de Monès, E., Larmonier, N., Soubeyran, P., & Ravaud, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.044 · Cited by 194
Mu, W., Tunali, I., Gray, J. E., Qi, J., Schabath, M. B., & Gillies, R. J. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04625-9 · Cited by 194
Tokito, T., Azuma, K., Kawahara, A., Ishii, H., Yamada, K., Matsuo, N., Kinoshita, T., Mizukami, N., Ono, H., Kage, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.020 · Cited by 193
Current state of immunotherapy for non-small cell lung cancer
Malhotra, J. D., Jabbour, S. K., & Aisner, J. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.01 · Cited by 193
Li, H. Y., McSharry, M. V., Bullock, B., Nguyen, T. T., Kwak, J., Poczobutt, J. M., Sippel, T. R., Heasley, L. E., Weiser-Evans, M. C. M., Clambey, E. T., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0365 · Cited by 193
Komiya, T., & Huang, C. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00423 · Cited by 193
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Kargl, J., Zhu, X., Zhang, H., Yang, G. H. Y., Friesen, T. J., Shipley, M., Maeda, D. Y., Zebala, J. A., McKay-Fleisch, J., Meredith, G. D., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130850 · Cited by 193
Yan, Y., Sun, D., Hu, J., Chen, Y., Sun, L., Yu, H., Xiong, Y., Huang, Z., Xia, H., Zhu, X., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01998-y · Cited by 193
Epigenetics and immunotherapy: The current state of play
Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 192
Sun, L., Zhang, L., Yu, J., Zhang, Y., Pang, X., Ma, C., Shen, M., Ruan, S., Wasan, H. S., & Qiu, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58674-4 · Cited by 192
Gong, J., Le, T. Q., Massarelli, E., Hendifar, A. E., & Tuli, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0361-7 · Cited by 191
Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
Atchley, W. T., Álvarez, C., Saxena, S., Schwartz, T. A., Ishizawar, R. C., Patel, K. P., & Rivera, M. P. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.02.032 · Cited by 193
Goldfarb, L., Duchemann, B., Chouahnia, K., Zelek, L. H., & Soussan, M. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0473-1 · Cited by 190
Hong, L., Negrao, M. V., Dibaj, S. S., Chen, R., Reuben, A., Bohac, J. M., Liu, X., Skoulidis, F., Gay, C. M., Cascone, T., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.026 · Cited by 190
Sedighzadeh, S. S., Khoshbin, A. P., Razi, S., Keshavarz‐Fathi, M., & Rezaei, N. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1241 · Cited by 190
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
Powell, S. F., Rodríguez‐Abreu, D., Langer, C. J., Tafreshi, A., Paz-Ares, L. G., Kopp, H., Rodríguez‐Cid, J. R., Kowalski, D. M., Cheng, Y., Kurata, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.020 · Cited by 188
Self-citationHuman leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali, O., Berner, F., Bomze, D., Fässler, M., Diem, S., Cozzio, A., Jörger, M., Früh, M., Driessen, C., Lenz, T. L., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.009 · Cited by 187
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
He, Y., Rivard, C. J., Rozeboom, L. M., Yu, H., Ellison, K. E., Kowalewski, A. A., Zhou, C., & Hirsch, F. R. (2016) · Cancer Science · doi:10.1111/cas.12986 · Cited by 187
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma
Momcilovic, M., Bailey, S. T., Lee, J. T., Fishbein, M. C., Braas, D., Go, J. L., Graeber, T. G., Parlati, F., Demo, S. D., Li, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.002 · Cited by 187
PD-L1/PD-1 Axis in Glioblastoma Multiforme
Litak, J., Mazurek, M., Grochowski, C., Kamieniak, P., & Roliński, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215347 · Cited by 187
Verheijden, R. J., May, A. M., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Boers‐Sonderen, M. J., van der Hoeven, J. J. M., Hospers, G. A. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3322 · Cited by 187
Rasul, M. F., Hussen, B. M., Salihi, A. B., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri‐Fard, S., Basiri, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01487-4 · Cited by 187
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186
Suresh, K., Psoter, K. J., Voong, K. R., Shankar, B., Forde, P. M., Ettinger, D. S., Marrone, K. A., Kelly, R. J., Hann, C. L., Levy, B., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.016 · Cited by 186
Self-citationSpigel, D. R., McCleod, M., Jotte, R. M., Einhorn, L. H., Horn, L., Waterhouse, D. M., Creelan, B., Babu, S., Leighl, N. B., Chandler, J. C., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.010 · Cited by 186
Self-citationWang, Z., Wu, L., Li, B., Cheng, Y., Li, X., Wang, X., Han, L., Wu, X., Fan, Y., Yu, Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00727 · Cited by 186
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
Novel therapeutic targets on the horizon for lung cancer
Tan, W.-L., Jain, A., Takano, A. M., Newell, E. W., Iyer, N. G., Lim, W., Tan, E.-H., Zhai, W., Hillmer, A. M., Tam, W. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30123-1 · Cited by 185
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 188
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J. P., & Collins, D. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 185
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis
Rubio‐Infante, N., Ramírez‐Flores, Y. A., Castillo, E. C., Lozano, O., García‐Rivas, G., & Torre‐Amione, G. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2289 · Cited by 185
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot, J., Lazarovici, J., Tieu, A., Champiat, S., Voisin, A.-L., Ebbo, M., Godeau, B., Michel, M., Ribrag, V., & Lambotte, O. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.014 · Cited by 184
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
Takada, K., Okamoto, T., Shoji, F., Shimokawa, M., Akamine, T., Takamori, S., Katsura, M., Suzuki, Y., Fujishita, T., Toyokawa, G., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.006 · Cited by 183
Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.274 · Cited by 183
Salem, M. E., Puccini, A., Xiu, J., Raghavan, D., Lenz, H., Korn, W. M., Shields, A. F., Philip, P. A., Marshall, J. L., & Goldberg, R. M. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0143 · Cited by 183
Next generation sequencing‐based gene panel tests for the management of solid tumors
Nagahashi, M., Shimada, Y., Ichikawa, H., Kameyama, H., Takabe, K., Okuda, S., & Wakai, T. (2018) · Cancer Science · doi:10.1111/cas.13837 · Cited by 183
Haragan, A., Field, J. K., Davies, M. P. A., Escriu, C., Gruver, A. M., & Gosney, J. R. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.005 · Cited by 183
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
Onoi, K., Chihara, Y., Uchino, J., Shimamoto, T., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., & Takayama, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051362 · Cited by 183
The immune mechanisms of abscopal effect in radiation therapy
Grass, G. D., Krishna, N., & Kim, S. (2015) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2015.10.003 · Cited by 182
George, S., Motzer, R. J., Hammers, H. J., Redman, B. G., Kuzel, T. M., Tykodi, S. S., Plimack, E. R., Jiang, J., Waxman, I. M., & Rini, B. I. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0775 · Cited by 182
Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Hafeez, U., Gan, H. K., & Scott, A. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.010 · Cited by 182
Chuzi, S. E., Tavora, F. R. F., Cruz, M. R. D. S., Costa, R. L. B., Chae, Y. K., Carneiro, B. A., & Giles, F. J. (2017) · Cancer Management and Research · doi:10.2147/cmar.s136818 · Cited by 181
Xing, P., Zhang, F., Wang, G., Xu, Y., Li, C., Wang, S., Guo, Y., Cai, S., Wang, Y., & Li, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0779-6 · Cited by 181
Chen, Y., Gao, M., Huang, Z., Yu, J., & Meng, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00940-z · Cited by 181
Okuma, Y., Hosomi, Y., Nakahara, Y., Watanabe, K., Sagawa, Y., & Homma, S. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.023 · Cited by 180
Neutrophil Heterogeneity in Cancer: From Biology to Therapies
Lecot, P., Sarabi, M., Pereira-Abrantes, M., Mussard, J., Koenderman, L., Caux, C., Bendriss‐Vermare, N., & Michallet, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02155 · Cited by 180
Majzner, R. G., Simon, J. S., Grosso, J. F., Martinez, D., Pawel, B. R., Santi, M., Merchant, M. S., Geoerger, B., Hezam, I., Marty, V., et al. (2017) · Cancer · doi:10.1002/cncr.30724 · Cited by 179
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Diggs, L. P., & Hsueh, E. C. (2017) · Biomarker Research · doi:10.1186/s40364-017-0093-8 · Cited by 179
Fujii, T., Colen, R. R., Bilen, M. A., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Tsimberidou, A. M., Jankú, F., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0534-0 · Cited by 179
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 179
Current and Future Treatment Strategies for Rhabdomyosarcoma
Chen, C. Y., García, H. D., Scheer, M., & Henssen, A. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01458 · Cited by 180
Kawakami, H., Tanizaki, J., Tanaka, K., Haratani, K., Hayashi, H., Takeda, M., Kamata, K., Takenaka, M., Kimura, M., Chikugo, T., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0453-0 · Cited by 178
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression
Long, G. V., Weber, J. S., Larkin, J., Atkinson, V. G., Grob, J., Schadendorf, D., Dummer, R., Robert, C., Márquez‐Rodas, I., McNeil, C. M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1588 · Cited by 178
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Hunter, K. A., Socinski, M. A., & Villaruz, L. C. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0308-6 · Cited by 178
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Wang, S., Cowley, L. A., & Liu, X. (2019) · Molecules · doi:10.3390/molecules24183214 · Cited by 178
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Reungwetwattana, T., Liang, Y., Zhu, V. W., & Ou, S. I. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.011 · Cited by 177
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 180
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Majem, M., Juan, Ó., Insa, A., Reguart, N., Trigo, J. M., Carcereny, E., García‐Campelo, R., García, Y. G., Guirado, M., & Provencio, M. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1978-1 · Cited by 178
Metadata
- Authors
- Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B., & Spigel, D. R.
- Affiliations
- City Of Hope National Medical Center (US)
- The Netherlands Cancer Institute (NL)
- University of Perugia (IT)
- Ruhrlandklinik (DE)
- Russian Cancer Research Center NN Blokhin (RU)
- Moffitt Cancer Center (US)
- University of Chicago (US)
- Oncology Hematology Care (US)
- Duke Medical Center (US)
- Massachusetts General Hospital (US)
- Fakultní nemocnice Bulovka (CZ)
- University Hospital Heidelberg (DE)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Amphia Ziekenhuis (NL)
- Hospital Universitario Virgen del Rocío (ES)
- LungenClinic Grosshansdorf (DE)
- Bristol-Myers Squibb (United States) (US)
- Tennessee Oncology (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-09
- Volume
- 373
- Issue
- 2
- Pages
- 123-135
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4681400
- OpenAlex
- W2156353875
- Cited by
- 8,447
- References
- 22
- Citations by year
- 2026: 204 · 2025: 332 · 2024: 525 · 2023: 627 · 2022: 718 · 2021: 928 · 2020: 1065 · 2019: 969 · 2018: 1066 · 2017: 1001 · 2016: 803 · 2015: 184
- FWCI
- 444.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, docetaxel, squamous cell non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, overall survival, progression-free survival, PD-L1 expression, treatment-related adverse events, second-line therapy, previously treated patients, response rate, treatment safety and efficacy comparison, immunotherapy versus chemotherapy
- MeSH terms
- Docetaxel, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Immunoglobulin G, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Taxoids, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
